Gilead Sciences, Inc. (NASDAQ:GILD) Stock Rating Reaffirmed by Maxim Group
Several other research firms have also issued reports on GILD. BidaskClub raised Gilead Sciences from a sell rating to a hold rating in a research report on Monday, July 24th. Robert W. Baird reissued an outperform rating and set a $87.00 price target on shares of Gilead Sciences in a research report on Tuesday, July 25th. Leerink Swann reissued a hold rating and set a $74.00 price target on shares of Gilead Sciences in a research report on Tuesday, July 25th. Redburn Partners assumed coverage on Gilead Sciences in a research report on Wednesday, July 26th. They set a buy rating on the stock. Finally, J P Morgan Chase & Co set a $85.00 price target on Gilead Sciences and gave the company an overweight rating in a research report on Thursday. Twelve equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. Gilead Sciences currently has a consensus rating of Buy and an average target price of $80.31.
Shares of Gilead Sciences (GILD) traded up 0.151% during trading on Thursday, hitting $76.055. 2,633,278 shares of the stock were exchanged. The company has a market cap of $99.33 billion, a price-to-earnings ratio of 8.261 and a beta of 1.20. The firm has a 50 day moving average of $69.98 and a 200-day moving average of $68.63. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $82.10.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business’s revenue was down 8.2% compared to the same quarter last year. During the same period in the prior year, the company posted $3.08 EPS. On average, analysts forecast that Gilead Sciences will post $8.72 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Gilead Sciences, Inc. (NASDAQ:GILD) Stock Rating Reaffirmed by Maxim Group” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.watchlistnews.com/gilead-sciences-inc-nasdaqgild-stock-rating-reaffirmed-by-maxim-group/1463825.html.
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be given a $0.52 dividend. The ex-dividend date is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.74%. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.
In related news, EVP Gregg H. Alton sold 40,000 shares of the stock in a transaction on Friday, July 21st. The stock was sold at an average price of $74.00, for a total value of $2,960,000.00. Following the completion of the transaction, the executive vice president now owns 137,488 shares in the company, valued at approximately $10,174,112. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John C. Martin sold 73,333 shares of the stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the transaction, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $227,197,799. The disclosure for this sale can be found here. Insiders sold a total of 128,276 shares of company stock valued at $9,190,610 in the last quarter. 1.30% of the stock is currently owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Rockland Trust Co. raised its position in Gilead Sciences by 16.7% in the first quarter. Rockland Trust Co. now owns 178,245 shares of the biopharmaceutical company’s stock worth $12,106,000 after buying an additional 25,551 shares during the period. Linscomb & Williams Inc. increased its stake in shares of Gilead Sciences by 3.0% in the first quarter. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company’s stock valued at $358,000 after buying an additional 154 shares in the last quarter. Berkshire Asset Management LLC PA acquired a new stake in shares of Gilead Sciences during the first quarter valued at about $270,000. Sigma Planning Corp increased its stake in shares of Gilead Sciences by 7.7% in the first quarter. Sigma Planning Corp now owns 40,168 shares of the biopharmaceutical company’s stock valued at $2,728,000 after buying an additional 2,889 shares in the last quarter. Finally, Hollencrest Securities LLC increased its stake in shares of Gilead Sciences by 119.8% in the first quarter. Hollencrest Securities LLC now owns 7,723 shares of the biopharmaceutical company’s stock valued at $525,000 after buying an additional 4,210 shares in the last quarter. Institutional investors and hedge funds own 73.99% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.